title: SGLT-2 inhibition and glucagon: Cause for alarm?
abstract: Recent studies raised the alarm that the inhibition of sodium-coupled glucose transporter type-2 in humans increases endogenous glucose production rates by an unclear mechanism. Surprisingly, a potential explanation may be linked directly to the alpha-cell. Is this a mechanistic spoiler or an added benefit?
authors.affiliation: Departments of Internal Medicine (Endocrinology) and Cellular & Molecular Physiology, Yale School of Medicine, 300 Cedar St. PO 208020, New Haven CT 06520. Electronic address: Richard.Kibbey@yale.edu.
authors.forename: Richard G
authors.initials: RG
authors.lastname: Kibbey
mesh_terms: D000818:Animals; D001559:Benzhydryl Compounds / Q000737:chemistry*; D005260:Female; D005786:Gene Expression Regulation; D005934:Glucagon / Q000378:metabolism*; D050416:Glucagon-Secreting Cells / Q000378:metabolism*; D005960:Glucosides / Q000737:chemistry*; D006801:Humans; D008297:Male; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D051297:Sodium-Glucose Transporter 2; D005934:Glucagon
keywords: HNF4alpha; SGLT-2 inhibitors; alpha-cell; glucagon; glucose production